Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (13531)	8/17/1998 8:57:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

to all...some other options from the 10Q report and a little speculation. Vivus is in the process of securing a $10 mill equipt lease $7.5 mill up front $2.5 as certain financial milestones occur over the 3rd and 4th qtr. Other financing on receivables and a line of credit. Future plant in Ireland can also take advantage of equipt lease financing to max use of cash. Then there is also the cash flow from the international sales of Muse and cash and cash equiv on hand. ********************************************************************* Now onto the new products and R&D items: Vivus can form alliances with larger partners to help finance new products. A sorter term example of this could be for Alibra, in return Atraa and Janssen may secure the right to sell Alibra in the same countries that they will be selling Muse. A potential source of funds to assist with the last phase of testing and final FDA/MCA approvals. A longer term item may be funding for research on Gene Therapy, similar to what SmithKline did in 1993 with Zonagen for the ED product that they have been working on, that may or may not be on the market in 1999. SmithKline paid millions to assist in this research for future distribution rights. If JNJ and/or Astra or another large phar co may think that Gene Therapy shows promise and is several years off they may be in a position to help finance it's developement and secure distribution rights early on in the process.